Ser652

Site Information
PsPRKRVssSGLTDS SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 4690508

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 )
Disease tissue studied:	breast cancer ( 1 ) , leukemia ( 2 ) , acute myelogenous leukemia ( 2 )
Relevant cell line - cell type - tissue:	BT-20 (breast cell) ( 1 ) , HeLa (cervical) ( 3 , 4 ) , Jurkat (T lymphocyte) ( 5 ) , KG-1 (myeloid) ( 2 ) , MDA-MB-468 (breast cell) ( 1 )

Upstream Regulation
Treatments:	EGF ( 4 ) , SB202190 ( 4 )

References
1	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
2	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
3	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
4	Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808 19651622 Curated Info
5	Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46 19690332 Curated Info